Evidence map›Paper›PMID 27703159›Full record

ArticleThe Journal of antibiotics2017

Synthesis and structure-activity relationships of novel lincomycin derivatives part 3: discovery of the 4-(pyrimidin-5-yl)phenyl group in synthesis of 7(S)-thiolincomycin analogs.

Yoshinari Wakiyama, Ko Kumura, Eijiro Umemura, Satomi Masaki, Kazutaka Ueda, Yasuo Sato, Takashi Watanabe, Yoko Hirai, Keiichi Ajito

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yoshinari WakiyamaPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan.
Ko KumuraPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan.
Eijiro UmemuraPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan.
Satomi MasakiPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan.
Kazutaka UedaPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan.
Yasuo SatoPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan.
Takashi WatanabePharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan.
Yoko HiraiPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan.
Keiichi AjitoPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan.
Unitika (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel lincomycin derivatives possessing an aryl phenyl group or a heteroaryl phenyl group at the C-7 position via sulfur atom were synthesized by Pd-catalyzed cross-coupling reactions of 7(S)-7-deoxy-7-thiolincomycin (5) with various aryl halides. This reaction is the most useful method to synthesize a variety of 7(S)-7-deoxy-7-thiolincomycin derivatives. On the basis of analysis of structure-activity relationships of these novel lincomycin derivatives, we found that (a) the location of basicity in the C-7 side chain was an important factor to enhance antibacterial activities, and (b) compounds 22, 36, 42, 43 and 44 had potent antibacterial activities against a variety of Streptococcus pneumoniae with erm gene, which cause severe respiratory infections, even compared with our C-7-modified lincomycin analogs (1-4) reported previously. Furthermore, 7(S)-configuration was found to be necessary for enhancing antibacterial activities from comparison of configurations at the 7-position of 36 (S-configuration) and 41 (R-configuration).

Indexed as

Anti-Bacterial AgentsBacterial ProteinsLincomycinStreptococcus pneumoniaeStructure-Activity RelationshipAnti-Bacterial AgentsBacterial ProteinsLincomycin

Identifiers

PMID27703159
OpenAlexW2529761995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.